drugset / Trial / NCT03557983

Evaluation of Fenofibrate on Radiation-induced Skin Injury

NCT03557983

RandomizedParallel-groupSingle-blindTreatment

Summary

Fenofibrate is a specific ligand for PPARα, which has been used for the treatment of hypercholesterolemia, hypertriglyceridemia, diabetes and cardiovascular diseases for long time. Fenofibrate reduces low-density lipoprotein (LDL), very low density lipoprotein (VLDL) and triglyceride levels, while increases high-density lipoprotein (HDL) levels. PPARα has also shown antioxidant and anti-inflammatory properties. Fenofibrate confers cytoprotective effect against myocardial ischemia-reperfusion (I/R) injury in rats by suppressing cell apoptosis and ameliorates age-related renal injury through the activation of AMPK and SIRT1 signaling. However, the safety and effectiveness of fenofibrate on the progression of radiation-induced skin injury remain unknown. The purpose of this study is to determine whether topical application of fenofibrate is safe and effective for radiation-induced skin injury.

Timeline

Start
2018-06-13
Primary completion
2020-04-13
Completion
2020-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 0.4 mg/ml Topical

Indications